Patent application number | Description | Published |
20090012126 | Certain chemical entities, compositions, and methods - Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, and chemical entities, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described. | 01-08-2009 |
20090176307 | Compounds, Compositions and Methods - Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 07-09-2009 |
20090264466 | Certain Chemical Entities, Compositions and Methods - Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described. | 10-22-2009 |
20090275537 | Certain chemical entities, compositions, and methods - Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described. | 11-05-2009 |
20100069370 | COMPOUNDS, COMPOSITIONS AND METHODS - Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 03-18-2010 |
20100069453 | Certain Chemical Entities, Compositions, and Methods - Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed. | 03-18-2010 |
20110112154 | Compounds, compositions and methods - Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 05-12-2011 |
20110201584 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described. | 08-18-2011 |
20120088779 | HETEROCYCLIC SULFONAMIDES - Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 04-12-2012 |
20120135964 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described. | 05-31-2012 |
20120196842 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described. | 08-02-2012 |
20120232092 | HETEROCYCLIC SULFONAMIDES - Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 09-13-2012 |
20120289698 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE - Provided are compounds of Formula I: | 11-15-2012 |
20130040945 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are arctigenin derivatives, pharmaceutical compositions and methods of treatment of cancer are described. | 02-14-2013 |
20130053348 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described. | 02-28-2013 |
20130053384 | Certain Chemical Entities, Compositions, and Methods - Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of using these chemical entities, e.g., for treatment of cancer are described. | 02-28-2013 |
20130060025 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE - Provided are compounds of Formula I: | 03-07-2013 |
20130123224 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described. | 05-16-2013 |
20130123289 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE - Provided are compounds of Formula I: | 05-16-2013 |
20130143862 | CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE - Provided are compounds of Formula I: | 06-06-2013 |
20130150368 | CERTAIN AMINO-PYRIDINES AND AMINO-TRIAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE - Provided are compounds of Formula I: | 06-13-2013 |
20130267537 | HETEROCYCLIC SULFONAMIDES - Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 10-10-2013 |
20130345186 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described. | 12-26-2013 |
20140206709 | CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE - Provided are compounds of Formula I: | 07-24-2014 |
20140330011 | CERTAIN HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE - Provided are compounds of Formula I: | 11-06-2014 |
20140343068 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described. Specifically quinoxaline derivatives of Formula I and their use in modulating the activity of Braf and/or mutant Braf kinase to regulate and modulate abnormal or inappropriate cell proliferation, differentiation, or metabolism are disclosed. Also disclosed are methods of treating cancer associated with Braf and/or mutant Braf kinase activity in a subject, comprising administering the compounds of Formula I. | 11-20-2014 |
20150057276 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described. | 02-26-2015 |
20150057277 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are quinoxaline kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described. | 02-26-2015 |
20150072984 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are curcumin derivatives, pharmaceutical compositions and methods of treatment of cancer are described. | 03-12-2015 |